Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/50

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/200811MODIFIED CHIMERIC CORONAVIRUS SPIKE PROTEIN FOR ENHANCEMENT OF VIRAL TITERS
WO 29.09.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/GB2022/050759 Applicant IOSBIO LTD Inventor DREW, Jeffrey
The disclosure relates to the production of viral particles, in particular adenoviral particles for use in vaccines. Modified chimeric coronavirus spike antigens are disclosed, together with polynucleotides encoding said antigens, viral particles and methods of production/formulation of the viral particles.
2.WO/2022/195900RECOMBINANT MEASLES VIRUS
WO 22.09.2022
Int.Class C12N 15/45
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
45Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
Appl.No PCT/JP2021/017632 Applicant THE UNIVERSITY OF TOKYO Inventor YONEDA Misako
The present invention provides: a recombinant measles virus useful as a live vaccine against COVID-19; and a vector used for producing the recombinant measles virus. That is, the present invention is a recombinant measles virus in which a gene encoding a protein of corona virus SARS-CoV-2 is inserted between the N gene region and the P gene region in a measles virus gene; the recombinant measles virus in which the protein is the spike protein of SARS-CoV-2 or a partial protein thereof; and DNA in which a gene encoding a protein of SARS-CoV-2 is inserted into the region from the base at position 1686 to the base at position 1694 in the nucleotide sequence represented by SEQ ID NO: 2.
3.WO/2022/196699FOLLICULAR HELPER T (TFH) CELLS SPECIFIC TO SARS-COV-2 VIRUS
WO 22.09.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/JP2022/011707 Applicant OSAKA UNIVERSITY Inventor YAMASAKI, Sho
Provided are follicular helper T cells specific to SARS-CoV-2 virus. On the basis of the discovery of a public Tfh TCR that is specific to a spike (S) protein common to various patients, the present disclosure identifies for the first time a SARS-CoV-2 virus-specific public TCR and the MHC and antigenic epitope thereof and thus promotes efficient immune responses, especially the response of B cells producing a neutralizing antibody. The present disclosure provides, for example, a SARS-CoV-2 virus-specific epitope-containing composition for inducing follicular T cells.
4.WO/2022/197840ADENOVIRUS SARS-COV-2 VACCINE
WO 22.09.2022
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/US2022/020604 Applicant THE WISTAR INSTITUTE Inventor ERTL, Hildegund, C., J.
The present invention includes methods and compositions useful for treating or preventing a coronavirus infection in a subject. In certain embodiments the treatment comprises adenoviral-based vaccines against SARS-CoV-2 viral proteins.
5.WO/2022/193552ADENOVIRUS TYPE 26 (AD26) VECTOR-BASED VACCINE FOR SARS‑COV‑2, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
WO 22.09.2022
Int.Class C12N 15/861
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
861Adenoviral vectors
Appl.No PCT/CN2021/114571 Applicant GUANGZHOU N BIOMED LTD. Inventor CHEN, Ling
Provided are an adenovirus type 26 (Ad26) vector-based vaccine for SARS‑CoV‑2, and a preparation method therefor. An optimized SARS‑CoV‑2 Spikes sequence as shown in SEQ ID NO. 1 is loaded on the Ad26 vector.
6.WO/2022/193553INFLUENZA VIRUS VECTOR-BASED NOVEL CORONAVIRUS VACCINE AND PREPARATION METHOD THEREFOR
WO 22.09.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2021/114572 Applicant GUANGZHOU N BIOMED LTD. Inventor CHEN, Ling
Disclosed in the present invention are an influenza virus vector-based novel coronavirus vaccine and a preparation method therefor. The vaccine can efficiently express two antigens, i.e., an HA antigen of the vaccine and an exogenous SC2R1 antigen, such that the vaccine can induce immune response of the two antigens to achieve the purpose of preventing influenza viruses and novel coronaviruses at the same time, and reduce the influences of two infectious diseases, i.e., influenza and novel coronaviruses, on the social economy, etc. Moreover, an influenza vaccine can be prepared and produced on a large scale on the basis of existing mature influenza platform technologies, and the influenza vaccine has a long use history and good safety.
7.WO/2022/187961MICROORGANISM DISPLAYING ANTIGENIC PROTEIN OF THE SARS-COV2 CORONAVIRUS
WO 15.09.2022
Int.Class C12N 1/21
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
21modified by introduction of foreign genetic material
Appl.No PCT/CA2022/050351 Applicant LES BIOTECHNOLOGIES ULYSSE INC. Inventor HURTUBISE, Yves
The present technology generally relates to a microorganism displaying antigenic proteins of the SARS-CoV2 coronavirus on its surface, to methods of preparing same, to composition comprising such microorganism and to methods for treatment of SARS-CoV2 related infections in subjects.
8.2604692Method for preparing recombinant subunit vaccine against novel coronavirus
GB 14.09.2022
Int.Class C07K 1/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
14Extraction; Separation; Purification
Appl.No 202115860 Applicant BEIJING SHANGWEI BIOTECHNOLOGY DEV CO LTD Inventor SHENGLI BI
The method includes: transfecting a plasmid into E. coli inserted with a nucleic acid fragment corresponding to the novel coronavirus receptor binding domain fused to a tetanus toxin sequence (RBD-TT); culturing the E.coli to express the RBD-TT fusion protein; lysing the bacterial cells and separating an inclusion body crude extract of the RBD-TT recombinant protein; dissolving the crude extract in a denaturing buffer solution containing 7.5-8.5 M urea, arginine, reduced glutathione and glycerol at pH 9-10, and purifying by anion exchange chromatography; diluting the crude sample of RBD-TT recombinant protein with a diluent; filtering, renaturing with renaturation solutions comprising lower arginine and glutathione concentrations than the denaturing solution to obtain a renatured protein; purifying the recombinant renatured protein by anion exchange chromatography.
9.115025212用于预防猪繁殖与呼吸综合征的mRNA疫苗及制备方法
CN 09.09.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No 202210697798.4 Applicant 天康制药(苏州)有限公司 Inventor 贺笋
本发明涉及mRNA疫苗技术领域,尤其是涉及用于预防猪繁殖与呼吸综合征的mRNA疫苗及制备方法。本发明利用猪繁殖与呼吸综合征病毒的结构蛋白和非结构蛋白,开发一种预防猪繁殖与呼吸综合征的mRNA疫苗,该疫苗使用后能够模拟天然感染的过程,在机体细胞内被翻译、修饰,可以被MHCI类分子和MHCII类分子呈递,诱发更强的细胞免疫和体液免疫应答,即双重功效。并且,本发明提供的mRNA具有自佐剂效应,无需进行佐剂筛选,即工序简化,功能强大。
10.WO/2022/179318S PROTEIN R815 SITE-BASED CORONAVIRUS INTERVENTION METHOD AND PRODUCT
WO 01.09.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2022/070763 Applicant INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES Inventor MENG, Guangxun
Provided in the present invention are an S protein R815 site-based novel coronavirus intervention method and a product. Particularly, provided in the present invention are an antigen peptide and a vaccine polypeptide of novel coronavirus. Further provided in the present invention are a vaccine composition containing the antigen peptide or the vaccine polypeptide and the use thereof. Experiments show that the antigen peptide or the vaccine polypeptide of the present invention can effectively prevent S protein from producing cell fusion and infection effects, thereby effectively preventing the infection of novel coronavirus.